RegenCell BioScience Holdings (RGC)

[shinhari1309]

Similarities between the top-performing IPOs in 2021 and 2022.

According to stockanalysis.com/ipos/2021/, Regencell Bioscience ($RGC) is now the best-performing stock of all 2021 IPOs. RGC is still rated first as of August 1, 2022, having gained 237 percent more than its $9.50 IPO price.

A recently traded stock that has skyrocketed after its mid-July 2022 AMTD Digital $HKD debut (as of August 3, 2022)

The controlling shareholder, AMTD Group Company Limited, was founded by billionaire Li Ka-shing’s CK Hutchison Holdings Limited in 2003. The IPO price of HKD was $7.80, and it closed at $742.00 on August 1, 2022, a rise of over 9,000 percent. The leading company at the moment is Regencell Bioscience, $RGC. Despite RGC leading all 2021 IPOs in performance, HKD is currently outperforming RGC.

Due to HKD's rapid growth, which has resulted in an astonishing 90 times bagger in a short period of time, the company has attracted a lot of short positions.

For HKD, the major shareholder has approximately 88.7 percent of the shares, whereas RGC major shareholders holds approximately 81.2 percent. The float of both businesses is small.

https://www.benzinga.com/general/biotech/22/08/28316977/a-look-into-the-top-performing-ipo-stock-of-2021